Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : TAK-994 Receives Breakthrough-Therapy Designation From FDA

07/28/2021 | 09:49am EDT


ę MT Newswires 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
11:11aMIRUM PHARMACEUTICALS : Partners With Takeda Over Developing, Commercializing Liver Diseas..
MT
08:10aTAKEDA PHARMACEUTICAL : Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Ag..
BU
06:39aMirum Inks Japan License for Maralixibat With Takeda
DJ
09/16TAKEDA PHARMACEUTICAL : Continues to Advance Growth Strategy with Sale Of Non-Core Assets ..
PU
09/16TAKEDA PHARMACEUTICAL : EXKIVITY (mobocertinib) Approved by U.S. FDA as the First Oral The..
AQ
09/16THERMO FISHER SCIENTIFIC : FDA Approves Tissue-Based NGS Companion Diagnostic for Takeda's..
AQ
09/16Adium Pharma S.A. entered into an agreement to acquire portfolio of five pharmaceutical..
CI
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : Exkivity Wins FDA Approval for Treatment of Lung Cancer with EGFR ..
MT
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 31 001 M 31 001 M
Net income 2022 253 B 2 319 M 2 319 M
Net Debt 2022 3 472 B 31 786 M 31 786 M
P/E ratio 2022 23,5x
Yield 2022 4,79%
Capitalization 5 911 B 54 104 M 54 111 M
EV / Sales 2022 2,77x
EV / Sales 2023 2,64x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 759,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 28,9%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.11%54 771
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000